
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is showing promising growth with Q4/25 revenue up 18% year-over-year, driven by new customer additions, the US launch of larger-sized OviTex PRS products, and international sales growth. Their OviTex unit sales and PRS unit sales also showed healthy increases of 20% and 12%, respectively. Despite falling slightly below gross margin estimates, the company's EPS of ($0.17) was above consensus estimates.
Bears say
TELA Bio is facing significant challenges with their sales force restructuring and strategic challenges, as evidenced by their lowered 2026 outlook and continued contraction in their stock. While their portfolio may offer potential, execution remains a key concern and it may take time for their new strategy to gain traction and drive revenue growth, leading to a cautious outlook on the stock. Furthermore, the company's dependence on regulatory approvals, potential for future losses and dilution, and uncertainty surrounding reimbursement for their products add additional layers of risk for investors to consider.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares